Rating History for GlaxoSmithKline (GSK) by Morgan Stanley
| Date | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|
| 1/23/2024 | Mark Purcell | New Coverage | Equalweight (N/A) |
44.00 (N/A) |
39.68 (51.96) |
30.95% | Details |
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
| Date | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|
| 1/23/2024 | Mark Purcell | New Coverage | Equalweight (N/A) |
44.00 (N/A) |
39.68 (51.96) |
30.95% | Details |
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||